This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Eoflow barred from making and selling EOPatch in trade secret dispute with Insulet, Massachusetts federal court orders

( October 6, 2023, 15:14 GMT | Official Statement) -- MLex Summary: South Korean insulin pump maker Eoflow has been hit with a preliminary injunction from the US District Court of Massachusetts, barring it from manufacturing or selling products allegedly developed using Insulet Corporation’s trade secrets, according to an order published today. The order also prohibits Eoflow from disclosing technical information related to its EOPatch device, including designs and software algorithms, linked to Insulet's Omnipod technology. The injunction, which remains in effect pending trial, requires Insulet to post a $1 million bond.Court document attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login